Hatem A. Azim

Hatem A. Azim

Auto-generated profile, based on publicly available information

Hatem A. Azim

Cairo Cure Oncology Center, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
LSLuigi Santoro
Luigi Santoro
Lucia Del MastroLucia Del Mastro
Lucia Del Mastro
BNBastien Nguyen
Bastien Nguyen
LLLuca Livraghi
Luca Livraghi
HAHatem A. Azim
Hatem A. Azim

10 October 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
EBEva Blondeaux
Eva Blondeaux
MBMarco Bruzzone
Marco Bruzzone
MPMarta Perachino
Marta Perachino
RARichard A Anderson
Richard A Anderson
Fedro Alessandro Alessandro PeccatoriFedro Alessandro Alessandro Peccatori
Fedro Alessandro Alessandro Peccatori
PURPOSE: Many patients and physicians remain concerned about the potential detrimental effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and maternal safety. This systematic review and meta-analysis aimed at providing updated evidence on these topics. METHODS: A systematic literature review was conducted to identify studies including patients with a pregnancy after BC (PROSPERO number CRD42020158324). Likelihood of pregnancy after BC, their reproductive outcomes, and maternal safety were assessed. Pooled relative risks, odds ratios (ORs), and hazard ratios (HRs) with 95% CIs were calculated using random effects models. RESULTS: Of 6,462 identified records, 39 were included involving 8,093,401 women from the general population and 112,840 patients with BC of whom 7,505 had a pregnancy after diagnosis. BC survivors were significantly less likely to have a subsequent pregnancy compared with the general population (relative risk, 0.40; 95% CI, 0.32 to 0.49). Risks of caesarean section (OR, 1.14; 95% CI, 1.04 to 1.25), low birth weight (OR, 1.50; 95% CI, 1.31 to 1.73), preterm birth (OR, 1.45; 95% CI, 1.11 to 1.88), and small for gestational age (OR, 1.16; 95% CI, 1.01 to 1.33) were significantly higher in BC survivors, particularly in those with previous chemotherapy exposure, compared with the general population. No significantly increased risk of congenital abnormalities or other reproductive complications were observed. Compared to patients with BC without subsequent pregnancy, those with a pregnancy had better disease-free survival (HR, 0.66; 95% CI, 0.49 to 0.89) and overall survival (HR, 0.56; 95% CI, 0.45 to 0.68). Similar results were observed after correcting for potential confounders and irrespective of patient, tumor, and treatment characteristics, pregnancy outcome, and timing of pregnancy. CONCLUSION: These results provide reassuring evidence on the safety of conceiving in BC survivors. Patients' pregnancy desire should be considered a crucial component of their survivorship care plan.

26 October 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
NKNiels Kroman
Niels Kroman
LALieveke Ameye
Lieveke Ameye
Octavi CórdobaOctavi Córdoba
Octavi Córdoba
ÁPÁlvaro Pinto-Marín
Álvaro Pinto-Marín
HAHatem A Azim
Hatem A Azim
Safety of pregnancy in women with history of estrogen receptor (ER)–positive breast cancer remains controversial. In this multicenter case–control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients’ outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.

1 November 2016 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
APAna Catarina Pinto
Ana Catarina Pinto
LALieveke Ameye
Lieveke Ameye
LJLynn Jongen
Lynn Jongen
Lucia Del MastroLucia Del Mastro
Lucia Del Mastro
HJHatem A Azim Jr
Hatem A Azim Jr
Limited data are available on the prognostic performance of Adjuvant! Online (AOL) and Nottingham Prognostic Index (NPI) in young breast cancer patients. This multicentre hospital-based retrospective cohort study included young (40 years) and older (55–60 years) breast cancer patients treated from January 2000 to December 2004 at four large Belgian and Italian institutions. Predicted 10-year overall survival (OS) and disease-free survival (DFS) using AOL and 10-year OS using NPI were calculated for every patient. Tools ability to predict outcomes (i.e., calibration) and their discriminatory accuracy was assessed. The study included 1283 patients, 376 young and 907 older women. Adjuvant! Online accurately predicted 10-year OS (absolute difference: 0.7%; P=0.37) in young cohort, but overestimated 10-year DFS by 7.7% (P=0.003). In older cohort, AOL significantly underestimated both 10-year OS and DFS by 7.2% (P<0.001) and 3.2% (P=0.04), respectively. Nottingham Prognostic Index significantly underestimated 10-year OS in both young (8.5%; P<0.001) and older (4.0%; P<0.001) cohorts. Adjuvant! Online and NPI had comparable discriminatory accuracy. In young breast cancer patients, AOL is a reliable tool in predicting OS at 10 years but not DFS, whereas the performance of NPI is sub-optimal.

10 August 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HAHatem A. Azim
Hatem A. Azim
SNSamuel M. Niman
Samuel M. Niman
APAnn H. Partridge
Ann H. Partridge
IDIsabelle Demeestere
Isabelle Demeestere
MRMonica Ruggeri
Monica Ruggeri
Fedro Alessandro Alessandro PeccatoriFedro Alessandro Alessandro Peccatori
Fedro Alessandro Alessandro Peccatori
PURPOSE: We investigated time to pregnancy, efficacy and safety of fertility preservation, and assisted reproductive technologies (ARTs) in women with early hormone receptor–positive breast cancer (BC) desiring future pregnancy. PATIENTS AND METHODS: POSITIVE is an international, single-arm, prospective trial, in which 518 women temporarily interrupted adjuvant endocrine therapy to attempt pregnancy. We evaluated menstruation recovery and factors associated with time to pregnancy and investigated if ART use was associated with achieving pregnancy. The cumulative incidence of BC-free interval (BCFI) events was estimated according to the use of ovarian stimulation at diagnosis. The median follow-up was 41 months. RESULTS: Two hundred seventy-three patients (53%) reported amenorrhea at enrollment, of whom 94% resumed menses within 12 months. Among 497 patients evaluable for pregnancy, 368 (74%) reported at least one pregnancy. Young age was the main factor associated with shorter time to pregnancy with cumulative incidences of pregnancy by 1 year of 63.5%, 54.3%, and 37.7% for patients age <35, 35-39, and 40-42 years, respectively. One hundred and seventy-nine patients (36%) had embryo/oocyte cryopreservation at diagnosis, of whom 68 reported embryo transfer after enrollment. Cryopreserved embryo transfer was the only ART associated with higher chance of pregnancy (odds ratio, 2.41 [95% CI, 1.75 to 4.95]). The cumulative incidence of BCFI events at 3 years was similar for women who underwent ovarian stimulation for cryopreservation at diagnosis, 9.7% (95% CI, 6.0 to 15.4), compared with those who did not, 8.7% (95% CI, 6.0 to 12.5). CONCLUSION: In POSITIVE, fertility preservation using ovarian stimulation was not associated with short-term detrimental impact on cancer prognosis. Pregnancy rates were highest among those who underwent embryo/oocyte cryopreservation followed by embryo transfer.

1 August 2015 in The Breast
Verified
Journal Article
Closed access
FZFlora Zagouri
Flora Zagouri
PLParaskevi Liakou
Paraskevi Liakou
Rupert BartschRupert Bartsch
Rupert Bartsch
Fedro Alessandro Alessandro PeccatoriFedro Alessandro Alessandro Peccatori
Fedro Alessandro Alessandro Peccatori
ATAlexandra Tsigginou
Alexandra Tsigginou
HAH.A. Azim
H.A. Azim